Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline

Servier has struck a deal to buy Edgewise Therapeutics’ muscular dystrophy business for $1.55 billion upfront, gaining control of a program that is on course to deliver pivotal data this year.